论文部分内容阅读
美国肝病研究学会年会(AASLD)是肝脏病学的重要会议,每年的会议都将世界各地的科学家汇聚美国,讨论在新药、新的治疗技术和新试验中所获得的新发现。目前,每10个美国人中就有1个患有肝脏疾病,而且肝脏疾病在每一个特定的人群中都有不同程度的传播,而大多教肝病与其生活方式无关。今年的AASLD于10月27-31日在美国波士顿举行,旨在加强肝脏疾病新技术的交流和传播,以唤起人们对肝脏健康的意识,预防和治疗肝病传播。会议报道了一批新的成就和成果,特别是乙型肝炎(简称乙肝)和丙型肝炎(简称丙肝)的治疗进展,获得了肝脏专家们的好评。
The annual meeting of the American Association of Liver Diseases (AASLD) is an important conference for hepatology. Each year, conferences bring scientists from all over the world to the United States to discuss new findings gained in new drugs, new therapeutic technologies and new tests. Currently, one out of every 10 Americans has liver disease, and liver disease spreads to varying degrees in each specific population, whereas most teaching liver disease has nothing to do with their lifestyle. This year’s AASLD was held in Boston, USA, from October 27 to 31, aiming to strengthen the exchange and dissemination of new technologies in liver disease so as to arouse people’s awareness of liver health and prevent and treat the spread of liver disease. The meeting reported on a number of new achievements and achievements, especially the progress of the treatment of hepatitis B (hepatitis B) and hepatitis C (hepatitis C), and won the praise of liver experts.